Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1625 of 2051 entries
View as:

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

Phase: N/A Priority: Normal
NCT ID: NCT05446870 Org: User:
Start: 07/25/22 End: 10/16/24 Due: 10/16/25

A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

Phase: N/A Priority: Normal
NCT ID: NCT01357148 Org: User:
Start: 03/31/09 End: 05/31/10 Due: 05/31/11

Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)

Phase: N/A Priority: Normal
NCT ID: NCT00726557 Org: User:
Start: 10/31/05 End: 01/31/09 Due: 01/31/10

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

Phase: N/A Priority: Normal
NCT ID: NCT00830076 Org: User:
Start: 12/02/08 End: 05/14/09 Due: 05/14/10

Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00896233 Org: User:
Start: 08/31/09 End: 01/31/10 Due: 01/31/11

Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT01059851 Org: User:
Start: 05/24/10 End: 07/15/10 Due: 07/15/11

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

Phase: N/A Priority: Normal
NCT ID: NCT00685776 Org: User:
Start: 03/24/08 End: 11/23/17 Due: 11/23/18

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Phase: N/A Priority: Normal
NCT ID: NCT03976375 Org: User:
Start: 06/26/19 End: 08/22/24 Due: 08/22/25

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

Phase: N/A Priority: Normal
NCT ID: NCT02332707 Org: User:
Start: 01/22/15 End: 12/06/16 Due: 12/06/17

A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Phase: N/A Priority: Normal
NCT ID: NCT00780039 Org: User:
Start: 10/01/03 End: 09/06/07 Due: 09/06/08

The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00002376 Org: User:
Start: - End: - Due: -

The Canadian Follow-up Program for the ATTRACT Study (P04868)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00748930 Org: User:
Start: 09/30/06 End: 10/31/07 Due: 10/31/08

A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)

Phase: N/A Priority: Normal
NCT ID: NCT01716156 Org: User:
Start: 01/18/13 End: 03/12/14 Due: 03/12/15

Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)

Phase: N/A Priority: Normal
NCT ID: NCT00335075 Org: User:
Start: 03/02/05 End: 02/23/06 Due: 02/23/07

A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

Phase: N/A Priority: Normal
NCT ID: NCT00473889 Org: User:
Start: 05/31/07 End: 12/31/08 Due: 12/31/09

PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)

Phase: N/A Priority: Normal
NCT ID: NCT00034671 Org: User:
Start: 01/31/01 End: 03/31/02 Due: 03/31/03

A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).

Phase: N/A Priority: Normal
NCT ID: NCT00969163 Org: User:
Start: 10/31/04 End: 06/30/05 Due: 06/30/06

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Phase: N/A Priority: Normal
NCT ID: NCT00325130 Org: User:
Start: 04/30/06 End: 04/30/07 Due: 04/30/08

Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)

Phase: N/A Priority: Normal
NCT ID: NCT01223339 Org: User:
Start: 10/31/10 End: 02/28/11 Due: 02/28/12

Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT01181804 Org: User:
Start: 06/30/10 End: 12/31/10 Due: 12/31/11

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00049842 Org: User:
Start: 10/31/02 End: 10/31/09 Due: 10/31/10

Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)

Phase: N/A Priority: Normal
NCT ID: NCT05285826 Org: User:
Start: 02/18/22 End: 05/25/29 Due: 05/25/30

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

Phase: N/A Priority: Normal
NCT ID: NCT04223778 Org: User:
Start: 02/18/20 End: 08/26/24 Due: 08/26/25

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

Phase: N/A Priority: Normal
NCT ID: NCT00619359 Org: User:
Start: 02/29/08 End: 06/30/09 Due: 06/30/10

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Phase: N/A Priority: Normal
NCT ID: NCT03665597 Org: User:
Start: 11/19/18 End: 12/04/23 Due: 12/04/24